1357476-67-5

Basic information

• Product Name: 4-broMo-2-(1,1,1-trifluoro-2-Methylpropan-2-yl)pyridine
• Synonyms: 4-broMo-2-(1,1,1-trifluoro-2-Methylpropan-2-yl)pyridine;4-broMo-2-(1,1,1-trifluoro-2-Methylpropan-2-yl);Pyridine, 4-bromo-2-(2,2,2-trifluoro-1,1-dimethylethyl)-;4-Bromo-2-(2,2,2-trifluoro-1,1-dimethylethyl)pyridine
• CAS NO: 1357476-67-5
• Molecular Formula: C9H9BrF3N
• Molecular Weight: 268.0736696
• Mol File: 1357476-67-5.mol
• Article Data: 5

Chemical Properties

• Boiling Point: 209.3±40.0 °C(Predicted)
• Appearance: /
• Density: 1.473±0.06 g/cm3(Predicted)
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• PKA: 2.29±0.10(Predicted)
• CAS DataBase Reference: 4-broMo-2-(1,1,1-trifluoro-2-Methylpropan-2-yl)pyridine(CAS DataBase Reference)
• NIST Chemistry Reference: 4-broMo-2-(1,1,1-trifluoro-2-Methylpropan-2-yl)pyridine(1357476-67-5)
• EPA Substance Registry System: 4-broMo-2-(1,1,1-trifluoro-2-Methylpropan-2-yl)pyridine(1357476-67-5)

Safety Data

• Hazardous Substances Data: 1357476-67-5(Hazardous Substances Data)

Usage

Synthesis

Different sources of media describe the Synthesis of 1357476-67-5 differently. You can refer to the following data:
1. To a solution of 18-6 (8.7 g, 42.40 mmol, 1 eq) in 1,2-dichloroethane (90 mL) was added Phosphorus(V) oxybromide (18.23 g, 63.60 mmol, 6.47 mL, 1.5 eq). The mixture was stirred at 80°C for 4 hours. TLC (Petroleum ether: Ethyl acetate: Ethanol =4:3:1) showed a part of starting material was remained. Another Phosphorus (V) oxybromide (6.08 g, 21.20 mmol, 2.16 mL, 0.5 eq) was added into the mixture. The reaction mixture was stirred at 80°C for another 3 hours. TLC (Petroleum ether: ethyl acetate: ethanol=4:3:1) showed the starting material was consumed completely. The mixture was combined with another batch (1 g scale) and then poured into ice saturated sodium bicarbonate solution (300 mL) and adjust the pH=7~8. The mixture was extracted with ethyl acetate (100 mLx3). The combined organic layers were washed with brine (100 mL), dried over anhydrous sodium sulfate, filtered, concentrated in vacuum. The residue was purified by column chromatography (SiO2, Petroleum ether: ethyl acetate=1:0 to 50:11) to give 18-7 (8.5 g, 31.71 mmol, 67.37% yield, 100% purity) as light yellow oil.
2. 4-broMo-2-(1,1,1-trifluoro-2-Methylpropan-2-yl)pyridine can be used as organic synthesis intermediate and pharmaceutical intermediate, mainly used in laboratory research and development process and chemical production process.

Upstream product

• 908267-63-0 4-bromo-2-isopropylpyridine 
• 1357476-66-4 2-(1,1,1-trifluoro-2-methylpropan-2-yl)pyridin-4(1H)-one 
• 1357476-64-2 2-(1,1,1-trifluoro-2-methylpropan-2-yl)-4H-pyran-4-one 
• 1163707-53-6 3,3,3-trifluoro-2,2-dimethylpropanoyl chloride 
• 889940-13-0 3,3,3-trifluoro-2,2-dimethylpropanoic acid 

Downstream Products

• 1357476-69-7 4-methyl-5-(2-(1,1,1-trifluoro-2-methylpropan-2-yl)pyridin-4-yl)thiazol-2-amine 
• 1217486-93-5 4-chloro-5-[2-(2,2,2-trifluoro-1,1-dimethyl-ethyl)-pyridin-4-yl]-thiazol-2-ylamine 
• 1217486-61-7 alpelisib 
• 1357476-68-6 C₁₅H₁₆F₃N₃OS 

Relevant articles and documents

Trifluoromethylation reaction on dimethyl substituted heterocyclic compound

The invention relates to a method for introducing a trifluoromethyl group through a trifluoromethylation reaction. A trifluoromethylation reagent used in the method is a Umemoto reagent, and a substrate is a wide dimethyl substituent-containing compound. The method has the advantages that the universality of the substrate is reflected, the reaction sites of the substrate acted by the Umemoto reagent in the past are always on the ring, and the site of the trifluoromethylation action is carbon on the dimethyl chain, which is a leap and breakthrough in the richness selection of the substrate andthe trifluoromethylation reaction.

Discovery of NVP-BYL719 a potent and selective phosphatidylinositol-3 kinase alpha inhibitor selected for clinical evaluation

Phosphatidylinositol-3-kinase α (PI3Kα) is a therapeutic target of high interest in anticancer drug research. On the basis of a binding model rationalizing the high selectivity and potency of a particular series of 2-aminothiazole compounds in inhibiting PI3Kα, a medicinal chemistry program has led to the discovery of the clinical candidate NVP-BYL719.

POLYMORPHS OF (S)-PYRROLIDINE-1,2-DICARBOXYLIC ACID 2-AMIDE 1-({4-METHYL-5-[2-(2,2,2-TRIFLUORO-1,1-DIMETHYL-ETHYL)-PYRIDIN-4-YL]-THIAZOL-2-YL}-AMIDE

The present invention relates to specific solid forms of (S)-pyrrolidine-1,2- dicarboxylic acid 2-amide l-(4-methyl-5-[2-(2,2,2-trifluoro-1,1-dimethyl-ethyl)-pyridin-4- yl]-thiazol-2-yl)-amide, and its solvates. The present invention further relates to processes for preparing said solid forms, pharmaceutical compositions comprising said solid forms, and methods of using said solid forms and pharmaceutical compositions to treat disease.